Task 8 -- Management and reporting. Semi-annual report, April 1--September 30, 1997

The task of addressing the environmental needs of nuclear defense complex sites under the US Department of Energy (DOE) Environmental Management (EM) Program requires the timely availability of appropriate cleanup technologies. Fostering the commercialization of these technologies is the mission of EM-50, the EM Program Office of Science and Technology. DOE`s Federal Energy Technology Center (FETC) pursues activities integral to the EM-50 mission through its Cooperative Agreement with the EM Office of Science and Technology (EMCA). The primary objective of Task 8 is to ensure the effectiveness of the EMCA. This is accomplished through (1) the coordination of internal EMCA activities and coordination with the FETC contractor`s representative, (2) the coordination and expansion of the EMCA, and (3) effective technical transfer

Toxaphene and Other Organochlorines in Arctic Ocean Fauna: Evidence for Atmospheric Delivery

Residues of the insecticide toxaphene (polychlorinated camphenes, PCCs) and other organochlorines (OCs) were determined in air, snow, seawater, zooplankton, and benthic amphipods collected from an ice island in the Canadian Arctic. The simultaneous determination of OCs in the atmospheric, hydrologic, and biologic compartments provided evidence of an atmospheric link to polar food chains. PCCs were identified and quantified using capillary gas chromatography - negative ion mass spectrometry. The order of OCs abundance in arctic air was: hexachlorocyclohexanes (HCHs) > hexachlorobenzene > PCCs > polychlorinated biphenyls (PCBs) > chlordanes > DDTs. In seawater, PCCs were exceeded only by the HCHs. Concentrations of PCBs and PCCs in two samples of benthic amphipods were the highest of the OCs detected.Key words: Arctic, Canada, pollution, organochlorines, air, water, biotaMots clés: Arctique, Canada, pollution, organochlorés, air, eau, biot

The superstring Hagedorn temperature in a pp-wave background

The thermodynamics of type IIB superstring theory in the maximally supersymmetric plane wave background is studied. We compute the thermodynamic partition function for non-interacting strings exactly and the result differs slightly from previous computations. We clarify some of the issues related to the Hagedorn temperature in the limits of small and large constant RR 5-form. We study the thermodynamic behavior of strings in the case of $AdS_3 \times S^3 \times T^4$ geometries in the presence of NS-NS and RR 3-form backgrounds. We also comment on the relationship of string thermodynamics and the thermodynamic behavior of the sector of Yang-Mills theory which is the holographic dual of the string theory.Comment: 22 pages, JHEP style, minor misprints corrected, some comments adde

Small deformations of supersymmetric Wilson loops and open spin-chains

We study insertions of composite operators into Wilson loops in N=4 supersymmetric Yang-Mills theory in four dimensions. The loops follow a circular or straight path and the composite insertions transform in the adjoint representation of the gauge group. This provides a gauge invariant way to define the correlator of non-singlet operators. Since the basic loop preserves an SL(2,R) subgroup of the conformal group, we can assign a conformal dimension to those insertions and calculate the corrections to the classical dimension in perturbation theory. The calculation turns out to be very similar to that of single-trace local operators and may also be expressed in terms of a spin-chain. In this case the spin-chain is open and at one-loop order has Neumann boundary conditions on the type of scalar insertions that we consider. This system is integrable and we write the Bethe ansatz describing it. We compare the spectrum in the limit of large angular momentum both in the dilute gas approximation and the thermodynamic limit to the relevant string solution in the BMN limit and in the full AdS_5 x S^5 metric and find agreement.Comment: 40 pages, amstex, 4 figures. V2: Corrected eqn (2.14) and some equations in section 5. Version to appear in JHE

The Bethe-Ansatz for N=4 Super Yang-Mills

We derive the one loop mixing matrix for anomalous dimensions in N=4 Super Yang-Mills. We show that this matrix can be identified with the Hamiltonian of an integrable SO(6) spin chain with vector sites. We then use the Bethe ansatz to find a recipe for computing anomalous dimensions for a wide range of operators. We give exact results for BMN operators with two impurities and results up to and including first order 1/J corrections for BMN operators with many impurities. We then use a result of Reshetikhin's to find the exact one-loop anomalous dimension for an SO(6) singlet in the limit of large bare dimension. We also show that this last anomalous dimension is proportional to the square root of the string level in the weak coupling limit.Comment: 35 pages, 3 figures, LaTeX; v2 references added, typos corrected, \Lambda fixed; v3 expanded discussion of higher loops in conclusion, matches published versio

Deconfining Phase Transition as a Matrix Model of Renormalized Polyakov Loops

We discuss how to extract renormalized from bare Polyakov loops in SU(N) lattice gauge theories at nonzero temperature in four spacetime dimensions. Single loops in an irreducible representation are multiplicatively renormalized without mixing, through a renormalization constant which depends upon both representation and temperature. The values of renormalized loops in the four lowest representations of SU(3) were measured numerically on small, coarse lattices. We find that in magnitude, condensates for the sextet and octet loops are approximately the square of the triplet loop. This agrees with a large $N$ expansion, where factorization implies that the expectation values of loops in adjoint and higher representations are just powers of fundamental and anti-fundamental loops. For three colors, numerically the corrections to the large $N$ relations are greatest for the sextet loop, $\leq 25$; these represent corrections of $\sim 1/N$ for N=3. The values of the renormalized triplet loop can be described by an SU(3) matrix model, with an effective action dominated by the triplet loop. In several ways, the deconfining phase transition for N=3 appears to be like that in the $N=\infty$ matrix model of Gross and Witten.Comment: 24 pages, 7 figures; v2, 27 pages, 12 figures, extended discussion for clarity, results unchange

A research agenda for seed-trait functional ecology

Trait-based approaches have improved our understanding of plant evolution, community assembly and ecosystem functioning. A major challenge for the upcoming decades is to understand the functions and evolution of early life-history traits, across levels of organization and ecological strategies. Although a variety of seed traits are critical for dispersal, persistence, germination timing and seedling establishment, only seed mass has been considered systematically. Here we suggest broadening the range of morphological, physiological and biochemical seed traits to add new understanding on plant niches, population dynamics and community assembly. The diversity of seed traits and functions provides an important challenge that will require international collaboration in three areas of research. First, we present a conceptual framework for a seed ecological spectrum that builds upon current understanding of plant niches. We then lay the foundation for a seed-trait functional network, the establishment of which will underpin and facilitate trait-based inferences. Finally, we anticipate novel insights and challenges associated with incorporating diverse seed traits into predictive evolutionary ecology, community ecology and applied ecology. If the community invests in standardized seed-trait collection and the implementation of rigorous databases, major strides can be made at this exciting frontier of functional ecology.Commonwealth Scientific and Industrial Research Organisation. Grant Number: R‐90470‐0

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity over Time in the COVID-OUT Trial

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination has decreasing protection from acquiring any infection with emergence of new variants; however, vaccination continues to protect against progression to severe coronavirus disease 2019 (COVID-19). The impact of vaccination status on symptoms over time is less clear. Methods: Within a randomized trial on early outpatient COVID-19 therapy testing metformin, ivermectin, and/or fluvoxamine, participants recorded symptoms daily for 14 days. Participants were given a paper symptom diary allowing them to circle the severity of 14 symptoms as none (0), mild (1), moderate (2), or severe (3). This is a secondary analysis of clinical trial data on symptom severity over time using generalized estimating equations comparing those unvaccinated, SARS-CoV-2 vaccinated with primary vaccine series only, or vaccine-boosted. Results: The parent clinical trial prospectively enrolled 1323 participants, of whom 1062 (80%) prospectively recorded some daily symptom data. Of these, 480 (45%) were unvaccinated, 530 (50%) were vaccinated with primary series only, and 52 (5%) vaccine-boosted. Overall symptom severity was least for the vaccine-boosted group and most severe for unvaccinated at baseline and over the 14 days (P <. 001). Individual symptoms were least severe in the vaccine-boosted group including cough, chills, fever, nausea, fatigue, myalgia, headache, and diarrhea, as well as smell and taste abnormalities. Results were consistent over Delta and Omicron variant time periods. Conclusions: SARS-CoV-2 vaccine-boosted participants had the least severe symptoms during COVID-19, which abated the quickest over time. Clinical Trial Registration. NCT04510194

Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial

Background: Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. Methods: We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194. Findings: Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37–54) and median BMI was 29·8 kg/m2 (IQR 27·0–34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2–8·2) in participants who received metformin and 10·4% (7·8–12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39–0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo. Interpretation: Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe. Funding: Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences